Successfully Selecting Sites For A Psychedelic Trial

The psychedelic clinical development pipeline is growing, and competition for experienced sites has the potential to slow startup timelines. That’s because, although more sites are beginning to participate in these trials, the number of experienced sites is still limited, leading to an overall dearth of options.

As a result, sometimes it’s necessary to explore selection of sites with psychiatric trial experience – but that have not worked with psychedelics specifically. Here are a few considerations to help you select the sites with the least risk.